Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evolving Paradigms in Recurrent/Metastatic SCCHN

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

Treatment Algorithms in Melanoma: Past, Present, and Future

Improving Survival in Glioblastoma Multiforme

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction to Checkpoint Inhibitors

New Standards of Care in ALK-Translocated Advanced NSCLC

Atopic Dermatitis Treatment Landscape

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Advancing Care Across the Spectrum of Pancreatic Cancer

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Immunotherapy for Peanut Allergy

Immune Checkpoint Inhibitors in Lung Cancer

PARP Inhibitors.

Locally Advanced Lung Cancer

Advances in Gastrointestinal Cancers

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

Going Beyond EXTREME in Head and Neck Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving Care Forward in Advanced Gastric Cancer

Immune Checkpoint Inhibitors in Lung Cancer

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Presentation transcript:

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Epidemiology of SCCHN

Tumor-Infiltrating Lymphocytes Are Present in Some HNCs

Tumor Immunity Cycle Goal: Activated T Cells Kill Tumor Cells

Modulation of the Immune System Through Checkpoint Inhibitor Pathways

Challenges in SCCHN Treatment

Case Study 1: 65-Year-Old With Stage IVB, HPV-Positive, Oropharynx Cancer

Nivolumab: CheckMate 141 Efficacy Data

Nivolumab: Data Related to Prior Treatments

Nivolumab: CheckMate 141 Biomarker Data

Pembrolizumab: Trials in R/M SCCHN

Durvalumab: Study 1108

Case Study 2: 69-Year-Old Patient With Stage IVB, HPV-Negative Larynx Cancer

Pseudoprogression

Ongoing Studies

Pembrolizumab Plus Epacadostat: Preliminary Data

Immune-Related AEs

Hypothyroidism

Pneumonitis

Take Home Messages

Abbreviations

Abbreviations (cont)